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INTRODUCTION
Oxidative stress (OS) is a condition of increased accumulation 
of reactive oxygen species (ROS) in the body. It is caused by 
the imbalance in the generation and scavenging of ROS in 
cells and tissues due to the inability of the biological system to 
detoxify them. Increased levels of ROS results in the oxidation 
of nucleic acids, proteins and lipids leading to irreversible 
damage to the cellular structures (Farías et al., 2017). Oxidative 
stress, directly or indirectly serves to influence the activation or 
deactivation of multiple signalling pathways. Thus OS plays an 
important role in the susceptibility of many chronic diseases 
(Prasad & Srivastava, 2020) like atherosclerosis (Matsuoka., 
2001), renal disorders (Pawlak et al., 2009), retinal diseases 
(Masuda et al., 2017), cardiovascular problems (Farías et al., 
2017), oral cancer (Yu et al., 2020), male infertility (Ahmad 
et al., 2010), neurodegenerative disorders (Shah et al., 2015) 
and a plethora of other diseases. As there exists a pathway 
crosstalk between COVID-19 and most of these comorbid 
conditions, they also lead to an increase in severity of COVID-19 
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Oxidative stress is the state of imbalance between the production of reactive oxygen species (free radicals) in the biological 
system and the ability of the body to detoxify them resulting in increased accumulation of free radicals in the cells. This stress 
leads to weakening of the immune system thus leading to higher susceptibility to other infections as well. This also includes 
the weakening of the respiratory tract leading to increased susceptibility of viral infections as in the case of COVID-19. 
Treatment for any kind of abnormality requires the identification of the key target proteins and pathways that are being 
altered. Withania somnifera is being used in the traditional medicinal system to improve health and longevity thus creating 
a sense of mental as well as physical well being. The present study utilises network pharmacological approach to predict the 
potential oxidative stress targets of the three major withanolides: withanolide A, withaferin A and withanone. Primarily, the 
targets of the individual withanolides were obtained from the Swiss target and DIGEP-pred databases and the GO terms and 
lead hits related to oxidative stress were retrieved from AMIGO2 database. Totally 40 correlative hits were obtained as anti 
stress targets of the withanolides, which were subjected to functional enrichment and protein–protein interaction analysis 
to study the enriched pathways underlying oxidative stress response. Further the eleven crucial targets of the four selected 
pathways were analysed using molecular docking analysis. A total of forty protein hits were obtained as oxidative stress targets 
of the withanolides. Further, the pathway enrichment of these forty target genes showed the AGE RAGE signalling pathway 
as highly enriched pathway. Therefore, the AGE RAGE signalling pathway along with its underlying pathways namely MAPK 
signalling pathway, FOXO pathway and PI3-AKT pathway were chosen among all the other enriched pathways. Further 
the molecular docking analysis of the eleven target proteins falling under these four pathways showed good docking scores 
of the withanolides with all the eleven targets with highest interaction against BCL2. From the above study, the biological 
targets and associated pathways of the withanolides have been retrieved. Thus the in silico approach undertaken in this study 
explores the role of the key withanolides in the antioxidant potential of the traditional medicinal plant Withania somnifera.
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infection (Chakrabarty et al., 2021). Also the treatment of 
COVID-19 patients with these comorbidities becomes more 
complex as there is no drug-drug interaction assessment studies 
with these comorbidity pathways (Barh et al., 2021). Further 
the increased cytokine production as a immune response against 
infections also serves as a source of ROS production which in 
turn can lead to increased viral replication (Bakadia et al., 2020). 
This increase in ROS levels is also accompanied by significant 
decrease in levels of vitamin A, C and E in plasma along with 
diminished antioxidant enzyme activities in COVID-19 patients 
(Muhammad et al., 2021). This in turn leads to cell apoptosis 
mediated by increased cytokine production as reported in severe 
COVID-19 cases. Thus oxidative stress plays important role in 
pathogenesis of COVID-19 infection (Chernyak et al., 2020).
Since several decades medicinal plants have been in use for the 
control and treatment of various clinical conditions. Further 
current researches focus more on these traditional medicinal 
plants which have been a cost effective and healthy source for 
the control of oxidative stress and prevention of OS related 
disorders (Palipoch & Thammarat, 2013). Medicinal plants 
and herbal extracts with natural antioxidants could potentially 
boost the body to defend against oxidative stress and thus 
influence the immune pathways to act against various diseased 
conditions. Withania somnifera (ashwagandha) as mentioned in 
Indian Pharmacopoeia (1985) is categorised as rasayan in Indian 
traditional medicinal system. This plant is reported in various 
studies to defend the body against various environmental 
factors, revitalise the body and thus increase longevity 
(Bhattacharya & Muruganandam, 2003). Recently, during this 
covid-19 pandemic, this magic herb has been promoted by the 
Indian government for use as an immune booster. Besides acting 
directly as an immune enhancer, it also helps to overcome any 
alterations in the immune activity caused by the psychological 
distress, anxiety and depression due the pandemic (Rajkumar, 
2020). Thus Ws is accurately referred to as an adaptogenic drug.
Withanolides, the bioactive compounds from Withania 
somnifera, are studied worldwide for its various therapeutic 
activities. They are reported to regulate oxidative stress and 
cytokine secretion (Balakrishna et al., 2021). Withaferin A is 
the most important and the first withanolide to be reported as 
early as 1962. Since then, nearly 400 closely related compounds 
have been studied under the class ‘withanolides’. Since the 
epigenetic mechanism and genes underlying oxidative stress 
overlaps with that of aging process, withaferin A that showed 
good resistance against oxidative stress also showed increase in 
lifespan when added as a feed in studies using drosophila(Koval 
et al., 2021). Withania somnifera extracts and its bioactive 
component withanone are found to control oxidative stress 
in neuroblastoma and glioblastoma cell lines thus protecting 
against neurodegeneration (Shah et al., 2015). Withanolide A 
has also reduced the ROS levels and thus increased lifespan 
in various strains of C. elegans (Nab et al., 2021). Further, 
in the molecular docking studies against the M-pro protein 
(the potential therapeutic target of COVID-19), withaferin A 
exhibited good binding affinity of -7.7 Kcal/mol among a pool 
of FDA approved anti-viral compounds and phytochemicals 
studied (Chandel et al., 2020). This interaction of withaferin 
A with M-pro was found to be much stronger than the other 
repurposed drugs including hydroxychloroquine (Dhawan et al., 
2021). Withanone also showed good docking potential similar 
to N3 inhibitor towards M-pro. Withanone was found to form 
polar bonds with Cys-145 residue of M-pro, which is important 
for its catalytic activity (Kumar et al., 2020). Thus all these three 
prime withanolides, withanolide A, withanone and withaferin 
A are known for its effect against oxidative stress and ROS 
accumulation along with increasing the well being and life span 
of the organisms. Hence all these three magical compounds can 
be used as adaptogenic or geroprotective drug.
Withania somnifera extracts as well as individual withanolides 
have been reported for various bioactivities along with their 
effect on a few genes associated with the respective disease. 
But, the complete set of targets that are acted upon by these 
withanolides have not been elucidated. Further, ashwagandha 
being an adaptogenic herb effective against various disorders it 
is necessary to understand its key targets. Since oxidative stress 
is one among the major factors of most of the disease worldwide, 
the exploration of the target proteins behind the antioxidant 
potential of this herb is essential. Further since oxidative stress 
is also reported to increase the comorbidities in COVID-19, it 
is also essential to understand the role of OS related genes and 
pathways on COVID-19. Therefore the current study is novel 
in that it aims to identify the potential targets of these three 
important withanolides and make use of network pharmacology 
approach to establish the various pathways altered by these 
withanolides to combat oxidative stress condition.
EXPERIMENTAL MATERIALS AND METHODS
Structure Retrieval and Pharmacological Profiling
The 3D structure in SDF format and canonical SMILES of the 
ligands withaferin A (Pubchem CID: 265237), withanolide A 
(Pubchem CID: 11294368) and Withanone (Pubchem CID: 
21679027) were retrieved from PubChem database (https://
pubchem.ncbi.nlm.nih.gov/). The SDF format file was then 
converted to PDB format using Open Babel GUI. The canonical 
SMILES was used as input files for Swiss ADME (http://
www.swissadme.ch/), a freely accessible web tool to study the 
Adsorption, Distribution, Metabolism, Excretion and Toxicity 
(ADMET) profile.
Prediction of Oxidative Stress Targets of Withanolides
Two freely accessible target protein databases “Swiss target” 
(http://www.swisstargetprediction.ch/) (Daina et al., 2019) and 
“DIGEP-pred” (http://www.way2drug.com/ge/) (Khanal et al., 
2020) were used to predict the biological targets of each ligand 
with biological activity (Pa) > 0. 5. The canonical SMILES 
were used as the query file for both the databases. The target 
sets from both the databases were then pooled to get the final 
targets of each withanolide. Following this, the target hits related 
to oxidative stress were extracted from AmiGO2 version 2.1.15 
(http://amigo.geneontology.org/) (Carbon et al., 2009) database 
using the key search term ‘oxidative stress’. A total of nine 
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AmiGO 2 gene ontology terms related to oxidative stress were 
chosen. All the nine target GO data sets were combined and 
duplicates removed to obtain the final list of oxidative stress 
related target proteins. Finally the targets of the individual 
withanolides overlapping with the targets of oxidative stress were 
retrieved by constructing venn diagrams in FunRich software 
(Fonseka et al., 2021). The gene set obtained were considered 
as anti-stress targets of that particular withanolide. The GO 
analysis of the obtained target hits were performed using 
Funrich software under three categories: cellular component, 
molecular function and biological process. Each of the enriched 
GO terms was plotted as graphs of the top 10 enriched terms.
Protein Protein Interaction (ppi) Network Construction
The final screened oxidative stress targets of the individual 
withanolides were pooled and protein set containing 40 entries 
was extracted and queried on STRING (https://string-db.org/) 
for Homo sapiens (Szklarczyk et al., 2019). The protein protein 
interaction network was used to observe the protein to protein 
co-relation and their pathway enrichment based on confidence 
scoring. The pathway enrichment of the genes was based on the 
KEGG pathway database. Among the enriched pathways, the 
pathways modulated by oxidative stress as obtained from published 
literature were chosen. The proteins of the highly enriched pathway 
AGE RAGE signalling pathway along with its underlying pathways 
namely FOXO signalling pathway, AKT signalling pathway and 
MAPK signalling pathway were selected for further analysis.
Molecular Docking
The predicted targets from the network analysis were then 
evaluated by molecular docking. The 3D structures of the 
eleven protein targets obtained from the selected four pathways: 
FOXO1(PDB ID: 3COA), MDM2 (PDB ID: 5AFG), JUN (PDB 
ID: 1JUN), BCL2 (PDB ID: 6QGG), SYK (PDB ID: 4XG2), 
PDGFRB (PDB ID: 2L6W), MAPK1(PDB ID: 6G54), MAPK8 
(PDB ID: 3O2M), MAPK14 (PDB ID: 7BDQ), PRKCD (PDB 
ID: 1PTR) and JAK2 (PDB ID: 5WIJ) were retrieved from 
protein data bank (PDB) (https://www.rcsb.org/). The water 
molecules and attached ligands were removed using Pymol 
2. Further the proteins were prepared by addition of charges 
and polar hydrogen atoms using Autodock tools. Each of 
these protein targets were then docked against withaferin A, 
withanolide A and withanone individually using Autodock 1.5.6. 
Both the protein and the ligand were considered as rigid during 
the docking process. The binding pose with the lowest binding 
energy among the ten different confirmations were extracted 
as the best docking pose. The docked files were then visualized 
using Discovery studio Biovia 2020 to study the binding pockets 
and the interacting residues.
RESULTS
Structure Retrieval and Adme Properties of Withanolides
The 3D structure and canonical SMILES of the three chosen 
ligands were retrieved from Pubchem Database (Figure 1). 
The ADME properties in terms of physicochemical properties, 
lipophilicity, water solubility, pharmacokinetics, druglikeness 
and medicinal chemistry were analysed (Table 1) using Swiss 
ADME. All the three withanolides being structurally similar, 
their physicochemical properties were found to be relatively 
same with molecular weight (470.606g/mol), six hydrogen 
acceptors and two hydrogen donors which were all within the 
permissible limits for a drug compound. All the three ligands 
showed no violations against the lipinski’s rule of 5.
Highly soluble compounds are highly absorbed. The solubility 
and lipophilicity of a drug compound is expressed in terms 
of log S mol/L and log p respectively. The absorption and 
distribution of the drug molecule is dependent on its aqueous 
solubility. The drugs with Log S values between -1 and -4 are 
considered optimum for better absorption and distribution 
(Lohidashan et al., 2018). The lower the log P values, stronger 
are the lipophilicity of the compound. Swiss ADME predicts the 
hydrophilic and lipophilic nature of compounds in terms of log 
P and log S programs like ILOGP, XLOGP3, WLOGP, ESOL 
and SILICOS-IT. The three compounds tested were found to 
be moderately soluble with log S values -4.67, -4.97, -4.56 for 
withanolide A, withaferin A and withanone respectively.
The metabolic capability of the drug compound is an important 
factor to be considered in drug discovery. The cytochrome 
P450, is a group of enzyme capable of metabolising a variety 
of xenobiotics. Of the 57 cytochrome P450s (CYPs) isoforms 
in humans, only five isoforms CYP3A4, CYP2D6, CYP2C19, 
CYP2C9 and CYP1A2 are responsible for about 90% of the drug 
metabolism (Aswathy et al., 2018). Withaferin A, withanolide A 
and withanone showed no inhibition to all the five isoforms of cyp 
450s. All the three ligands showed bioavailability score of 0.55. 
The skin permeation values were found to be around -6cm/s and 
synthetic accessibility score around 6. All these pharmacokinetic 
properties are within the permissible range described for human 
use, indicating its potential as a drug-like molecule.
Table 1: Physicochemical, pharmacokinetic and drug likeliness 
profile of the bioactive compounds
Compound name Withanolide 
A
Withaferin A Withanone
Molecular weight (g/mol) 470.60 470.66 470.60
No: heavy atoms 34 34 34
No: hydrogen bond acceptors 6 6 6
No: hydrogen bond donos 2 2 2
No: rotatable bonds 2 3 2
Polar surface area (Å2) 96.36 96.36 96.36
Log P (iLOGP) 3.68 3.39 3.71
Log S (ESOL) ‑4.67 ‑4.97 ‑4.56
GI absorption High High High
CYP (1A2, 2C19, 2C9, 2D6, 
3A4) inhibitor
No No No
Skin permeation LogKp cm/s ‑6.86 ‑6.45 ‑7.01
Bioavailability score 0.55 0.55 0.55
Synthetic accessibility 6.39 6.83 6.38
Lipinski (No: of violations) 0 0 0
Ghose (No: of violations) 1(atoms>70) 1(atoms>70) 1(atoms>70)
Veber (No: of violations) 0 0 0
Egan (No: of violations) 0 0 0
Muegge (No: of violations) 0 0 0
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Screening and Enrichment Analysis of Oxidative Stress 
Responsive Targets of Withanolides
The targets for withaferin A, withanolide A and withanone 
were obtained from Swiss target and DIGEP-pred platforms 
using their respective canonical SMILES file as an input. 
The targets from both the databases were then merged and 
duplicates removed. The final number of target proteins for 
each series obtained is presented table 2. The highest number 
of target genes were obtained for withanolide A with a total of 
317 targets followed by 289 and 273 targets for withanone and 
withaferin A respectively.
AmiGO 2 is an online free interactive gene ontology and 
annotation browser that helps to navigate and filter data from 
any specific ontology branch. The target genes underlaying 
oxidative stress response were obtained from AmiGO 2 
database using ‘oxidative stress’ as the search term. A total 
of nine gene ontology terms related to oxidative stress were 
selected and protein targets retrieved. All the data were then 
pooled to yield a final list of 572 genes responsible in stress 
response (Table 3).
The protein targets that were common between the withanolides 
and the oxidative stress related targets were interpreted by 
constructing venn diagrams using Funrich software. The 
common genes were considered as the oxidative stress targets 
of that withanolide. A total of 30, 27 and 31 oxidative stress 
target proteins were obtained for withanolide A, withaferin 
A and withanone respectively. Totally the 40 oxidative stress 
target hits of the withanolides were subjected to Gene Ontology 
(GO) enrichment analysis based on three categories: cellular 
component, molecular function and biological process using 
Funrich software. The top six GO terms that were significantly 
enriched among the 40 core targets were retrieved. The 
enrichment analysis on cellular component shows that highly 
significant GO terms were associated with the nucleus and 
cytoplasm (Figure 2a). Figure 2b shows the enriched GO terms 
of molecular function were protein serine/threonine kinase 
activity, protein-tyrosine kinase activity and catalytic activity. 
Among the biological processes, signal transduction and cell 
communication GO terms were found to be highly enriched 
(Figure 2c).
Protein-Protein Interaction Network and Pathway 
Enrichment Analysis
The protein-protein interaction network for this target set of 
40 proteins was constructed using STRING. The interaction 
network constituted of 125 edges for 40 nodes with average 
node degree of 6.25 and enrichment value of <1.0e-16. The 
pathway enrichment was based on KEGG pathway database 
in which a total of 112 pathways were found to be enriched. 
This included various pathways related to infectious diseases 
(tuberculosis, eipstein-barr virus infection, leishmaniasis, 
toxoplasmosis, salmonella infection, shigellosis, influenza A), 
pathways influencing cancer (pathways in cancer, renal cell 
carcinoma, pancreatic cancer, microRNAs in cancer, prostrate 
cancer, transcriptional misregulation in cancer, bladder cancer, 
apoptosis), diabetes (glucagon signalling pathway, typeII 
diabetes mellitus, insulin signalling pathway) and signalling 
pathways (neurotropin signalling pathway, GnRH signalling 
pathway, ErbB signalling pathway, prolactin signalling pathway, 
NOD like receptor signalling pathway, VEGF signalling 
pathway, chemokine signalling pathway). Among these enriched 
Table 2: Target proteins of the withanolides
Compound Swiss target DIGEP‑pred Total
Withanolide A 106 217 317
Withaferin A 102 174 273
Withanone 113 186 289




Pathway  No: of 
proteins
GO: 0000302 Response to reactive oxygen species 222
GO: 0034614 Cellular response to reactive oxygen species 126
GO: 0072593 Reactive oxygen species metabolic process 239
GO: 2000377 Regulation of ROS metabolic process 157
GO: 1901031 Regulation of response to reactive oxygen 
species
040
GO: 0006979 Response to oxidative stress 456
GO: 0034599 Cellular response to oxidative stress 305
GO: 1902882 Regulation of response to oxidative stress 101
GO: 1900407 Regulation of cellular response to oxidative 
stress
118
Figure 1: 3D Structure and Canonical SMILES of withaferin A, withanolide A and withanone
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pathways, only those pathways related to oxidative stress were 
chosen for further studies.
Thus the KEGG pathways chosen were AGE-RAGE signalling 
pathway, MAPK signalling pathway, FOXO signalling pathway 
and P13-AKT signalling pathway. Among the oxidative stress 
pathways chosen, AGE-RAGE signalling pathway was highly 
enriched with false discovery rate of 6.81e-09, followed by FOXO 
signalling pathway, P13 AKT signalling pathway and MAPK 
signalling pathway with false discovery rate of 4.32e-05, 0.00024 
and 0.00087 respectively. A total of eleven target proteins out 
of the forty targets of the withanolides fell under these chosen 
pathways. The interplay between these four selected pathways 
in controlling ROS accumulation is depicted in Figure 3. The 
STRING interaction network for these eleven target proteins 
was also constructed to study the interactions among them. 
The interaction network showed 32 edges for eleven nodes 
with average node degree of 5.82 and ppi enrichment value of 
2.85e-09 (Figure 4).
Molecular Docking
Various clinical and computational studies report the 
effectiveness of WS extracts as well as its phytocompounds 
in the control of Oxidative stress. Successfully, all the three 
withanolides generated good dock poses against the selected 
target genes with nearly same binding energies for each of the 
target proteins with minor changes in the binding site and 
interacting residues (Table 4).
All the three bioactives showed high binding energies against 
BCL2 protein with binding scores -9.08, -10.15 and -9.03 for 
withanolide A, withaferin A and withanone respectively. The 
withanolides withanolide A, withaferin A and withanone showed 
similar binding energies of -7.38, -7.37 and -7.41 with PDGFRB. 
Withanolide A and withaferin A formed two hydrogen bonds 
and withanone formed one hydrogen bond with PDGFRB 
respectively. Withanone showed the highest binding energy with 
MDM2 with a binding score of -9.23 and interacted with ten 
residues via alkyl bonds. This was followed up by withanolide A 
and withaferin A that interacted with seven and nine residues 
in the binding pocket and showed binding score of -9.01 
and -8.62 respectively. Whereas only withaferin A formed a 
single hydrogen bond with GLN A: 72 residue of MDM2.
Withaferin A showed the highest binding energy with three 
hydrogen bonds which was also higher compared to withanolide 
A and withanone with 1 and 2 hydrogen bonds. Withanolide 
Figure 2: Gene ontology enrichment analysis of the potential oxidative stress targets of withanolides
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A, withaferin A and withanone showed binding scores 
of -6.79, -6.39 and -6.66 against FOXO1 with 3(ALA F:159, TYR 
F:165, ASN F:216), 4 (ARG F:180, GLU F:178, SER C:234, GLY 
C:232) and 3(GLU F:229, ASN C:228, GLN F:185) hydrogen 
bonds respectively. Withaferin A strongly bound with JAK2 with 
a binding energy of -9.51 mediated by four hydrogen bonds. 
The interacting residues were ARG A: 715, PRO A: 700, ASN 
A: 673 and SER A: 633. Withanone and withanolide A showed 
binding energies of -9.15 and -8.74 with 1(THR A: 555) and 
2(SER A: 633 and LYS A: 581) hydrogen bonds respectively 
with JAK2. SYK showed binding energy of -9.19 forming three 
hydrogen bonds with GLU A: 452, GLU A: 420 and ASP A: 
512. Withanolide A and withanone formed 1(LEU A: 453) 
and 2 (ALA A: 451 and ASP A: 512) hydrogen bonds with SYK 
with binding energies -8.85 and -8.11 respectively. All the three 
bioactives formed 2 hydrogen bonds with JUN at different 
binding pockets. Withaferin A with the least binding energy 
against JUN interacted only with the A chain while withanolide 
A and withanone interacted with residues of both A and B chain 
of JUN. Withanolide A, withaferin A and withanone showed 
binding scores of 6.46, -6.16 and -6.52 against JUN respectively. 
All the three withanolides showed increased hydrogen bonding 
with PRKCD compared to the other proteins. PRKCD formed 
4, 3 and 6 hydrogen bonds with withanolide A, withaferin A 
and withanone with binding energies -8.12, -7.37 and -7.71 
respectively.
Withaferin A and withanone formed four hydrogen bonds 
with different residues of MAPK1 contributing to a binding 
score of -8.51 and -9.43 respectively. Whereas withanolide 
A formed a single hydrogen bond with GLU A: 33 residue 
of MAPK1 with binding energy -8.68. The highest binding 
energy with MAPK8 was exhibited by withanone which 
hydrogen bonded with LYS A: 336 and ASN A: 81 residues 
with binding energy -9.13. Withaferin A with binding 
score -8.72 also formed two hydrogen bonds with SER A: 
34 and MET A: 111 residues of MAPK8. Withanolide A 
with three hydrogen bonds showed a docking score of -8.99 
against MAPK8.
DISCUSSION
The adaptogenic potential of Withania somnifera as well 
as its withanolides can be used to control each stage in the 
pathophysiology of COVID-19 from the viral entry through 
immune suppression and cytokine production, inflammation and 
vascular permeabilisation to multi organ failure (Saggam et al., 
2021). The metabolic capability of the drug compound is an 
important factor to be considered in drug discovery. The in silico 
ADMET studies on withaferin A, withanolide A and withanone 
showed no violations against lipinski’s rule of five revealing the 
drug likeliness of all the three withanolides of interest. But in 
order to understand the mechanism of action of these individual 
withanolides or its combinations as in crude extracts, the 
interpretation of the biological targets and associated pathways 
of these drug compounds becomes a necessity. Though each of 
the withanolide showed around 300 protein targets, increased 
overlapping of the targets were observed which might be because 
Figure 3: Interplay between the four oxidative stress related pathways
TNF: Tumor necrosis factor; TNFR: Tumor necrosis factor receptor; GFs: Growth factor; GFR: Growth factor receptor; INS: Insulin; INSR: Insulin 
receptor; AGEs: Advanced glycation end products; RAGE: Advanced glycation end product receptor; TRADD: TNFR1 associated death domain 
protein; TRAF2: TNFR associated factor 2; ASK: Aspartate kinase; PKCδ: Serine/threonine protein kinase C delta; MEKK4: Mitogen activated 
protein kinase kinase 4; P38 MAPK: Mitogen activated protein kinase; MDM2: Mouse double minute 2 homology; Akt: Protein kinase B; SYK: 
Spleen associated tyrosine kinase; Raf &Ras: regulators of MAPK pathway; JNK: c-JUN N-terminal kinase; PI3K: phosphor inositol 3 kinase; 
PDK1: 3- phosphoinositide-dependent kinase 1; JAK2: Janus kinase 2; STAT3: Signal transducer and activator of transcription 3; FOXO: Forkhead 
box transcription factor; cJUN: Jun proto oncogene; NF-κB: Nuclear factor kappa B; Bcl2: B-cell lymphoma 2; IRS: Insulin receptor substrate 1; 
PIP3:Phosphatidylinositol 3,4,5 triphosphate; NADPH: Nicotinamide adenine dinucleotide phosphate; ROS: Reactive oxygen species
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all the withanolides are structurally similar with slight changes 
in the side chain or functional groups.
Since oxidative stress remains as a main cause of increased 
morbidity in COVID 19 cases, the pathways underlying the 
oxidative stress mechanism namely AGE RAGE signalling 
pathway, MAPK signalling pathway, PI3-AKT signalling pathway 
and FOXO signalling pathway were prioritised among the 
various enriched pathways. It was interesting to note that a 
similar study on the key target proteins and signalling pathways 
of COVID-19 also reported 517 target proteins enriched in 32 
signalling pathways including the above four pathways (Oh 
et al., 2021). Thus implicating the anti- COVID potential of 
the withanolides. Further AGE-RAGE signalling pathway is 
also reported to play an important role in COVID-19 infection 
as well as other comorbidities like diabetes, cardiovascular 
disease, cancer and GI disease that are associated with severity 
of COVID infection (Chakrabarty et al., 2021).
The protein-protein interaction and pathway enrichment 
analysis showed that AGE-RAGE signalling pathway was highly 
enriched among all other pathways associated with the target 
proteins. It is to be noted that though there are various sources 
of ROS in a biological system the mitochondrial oxidation and 
glycation processes remains the primary source. The glycation 
process leads to the accumulation of glycation end products 
(AGE) and its interaction with its receptors (RAGE) leads to 
production of ROS and cytokines via the AGE-RAGE signalling 
pathway. Among the two forms of RAGE protein, the soluble 
form (sRAGE) forms the extracellular domain that traps 
and prevents the binding of ligands to the membrane bound 
form (mRAGE), thus preventing the inflammatory reactions. 
The concentrations of sRAGE in the young asymptomatic 
COVID-19 patients were relatively higher than in non-COVID 
subjects. Whereas, the elder COVID-19 patients with severe 
lung injuries showed decreased sRAGE concentrations than 
in the control subjects (Kehribar et al., 2021). This implies 
the role of AGE-RAGE pathway in aging and its implications 
on COVID-19. Among the eleven targets studied, eight target 
proteins namely BCL2, FOXO1, JUN, PRKCD, JAK2, MAPK1, 
MAPK8 and MAPK14 were found to be associated with AGE-
RAGE signalling. Though all the three withanolides have shown 
good docking scores against these targets, the exact role of these 
withanolides on these genes as well the AGE-RAGE pathway is 
unknown. But from the experimental studies that have shown 
anti glycation activity of the withanolides and ashwagandha 
extracts it can be inferred that these withanolides bind well to 
these targets thus inhibiting glycation activity which in turn 
inhibits increased ROS production (Tupe et al., 2016).
The mitogen activated protein kinases (MAPK) also serves 
to be a component of AGE-RAGE signalling pathway. 
Several studies have also implicated the role of AGEs in the 
production of intracellular ROS and also the involvement of 
MAPK pathway and AKT pathway in AGE –RAGE signalling 
(Younessi & Yoonessi, 2011). Mitogen activated protein 
kinase (MAPK) cascade also referred to as extracellular signal 
regulated protein kinase (ERK) cascade play an important role 
in signal transmission by growth factors, immune modulators, 
cellular stress and other stimuli (Bardwell et al., 2009). The 
upregulation of p38 MAPK pathway was also observed in 
COVID-19 patients leading to inflammation and severe organ 
damage (Grimes & Grimes., 2020). Under normal conditions, 
AKT pathway is known to stabilise the homeostasis of the 
cells by regulating the oxidative metabolism leading to the 
generation of ROS on one hand and on the other hand 
suppresses FOXO pathway leading to the transcriptional 
activation of antioxidant enzymes. This mechanism plays 
an important role in maintaining the homeostasis of the 
biological system. The oxidative stress condition also leads 
to the phosphorylation and translocation of FOXO proteins 
to the nucleus. Stress activated FOXO proteins induce the 
expression of tumour suppressor genes leading to cell cycle 
arrest (Yoko et al., 2005). The activation of FOXO also 
regulates the immune (innate and adaptive) and inflammatory 
responses. The diminished anti-oxidant and anti-inflammatory 
responses in COVID-19 infected patients are the underlying 
cause for lung injury. The upregulation of FOXO balances 
Figure 4: Protein-protein interaction network of the oxidative stress 
related enriched pathways of the withanolide targets
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the concentration of pro-inflammatory molecules thus aiding 
repair of the damaged tissues (Cheema et al., 2021).
FOXO transcription factors are also negatively regulated by 
AKT activation. Both withanolide A and withaferin A are 
found to inhibit AKT pathway at certain concentrations thus 
leading to the activation of FOXO transcription (Wang et al., 
2019; Yan et al., 2018). The down regulation of AKT pathway 
leads to reduced ROS levels due to decreased mitochondrial 
activity and increased FOXO mediated antioxidant enzyme 
production (Dolado & Nebreda, 2008). Besides activation of 
FOXO by phosphorylation of the upstream region by AKT, 
it was found that in mammals, any extracellular signal that 
activates the AKT pathway is also found to directly inhibit the 
FOXO transcription factors. The upregulation of antioxidant 
enzymes and suppression of oxidative stress by withaferin A 
was inhibited by the addition of AKT inhibitor IV indicating 
its inhibitory role on AKT pathway (Yan et al., 2018). 
Withanolide A was also found to inhibit AKT pathway at higher 
concentrations but activated the same at lower concentrations 
(Wang et al., 2019).
The grid based Molecular docking simulation studies were 
carried out to study the binding potential of the withanolides 
against the anti-stress target proteins. Hydrogen bonds 
also play a key role in determining the strength of the 
intermolecular interactions as well as the three dimensional 
conformation adopted by the proteins. Further, the docking 
score differentiates the interacting ability of the compounds. 
Though the bioactives selected for the study are structurally 
similar, they show significantly different activities making them 
ideal candidates to be investigated through virtual screening 
and docking. Various studies have reported the antioxidant 
capability of anti-apoptotic protein BCL2 like the suppression 
of hyperglycemia-induced formation of advanced glycation 
end products (AGE) in endothelial cells and reduced ROS 
Table 4 : Molecular docking of the withanolides against the oxidative stress targets
Protein Ligand Binding 
Score
Interacting residues
BCL2 Withanolide A ‑9.08 ARG A: 139, LEU A: 137, MET A: 115, ALA A: 149, PHE A: 153, PHE A: 104, VAL A: 133
Withaferin A ‑10.15 ASP A: 140, GLU A: 136, LEU A: 137, VAL A: 133, PHE A: 153, MET A: 115, ALA A: 149
Withanone ‑9.03 GLU A: 136, ARG A: 139, LEU A: 137, VAL A: 133, MET A: 115, ALA 1:149, PHE A: 153, PHE A: 104
FOXO1 Withanolide A ‑6.79 ALA F: 159, TYR F: 196, TRP F: 160, TYR F: 165, ASN F: 216, ALA F: 166, HIS F: 220, SER F: 164
Withaferin A ‑6.39 TRP F: 236, GLU C: 229, ARG F: 180, GLU F: 178, TRP C: 236, LYS C: 233, SER C: 234, GLY C: 232
Withanone ‑6.66 GLU F: 229, ASN C: 228, LYS F: 233, TRP F: 236, GLN F: 185, LYS C: 233
MDM2 Withanolide A ‑9.01 TYR A: 100, HIS A: 96, LEU A: 54, VAL A: 93, ILE A: 61, MET A: 62, TYR A: 67
Withaferin A ‑8.62 PHE A: 55, ILE A: 61, VAL A: 93, VAL A: 75, TYR A: 67, GLN A: 72, LEU A: 54, ILE A: 99, LEU A: 57
Withanone ‑9.23 ILE A: 61, VAL A: 93, LEU A: 57, HIS A: 96, ILE A: 99, TYR A: 100, LEU A: 54, GLY A: 58, MET A: 62, TYR 
A: 67
JUN Withanolide A ‑6.46 LYS A: 288, GLN B: 290, ARG A: 302, LEU B: 294, GLU B: 293
Withaferin A ‑6.16 TYR B: 315, ASN B: 314, MET B: 313, VAL B: 312
Withanone ‑6.52 LYS B: 309, VAL B: 305, LEU A: 301, ARG B: 302, MET A: 300, THR A: 297
JAK2 Withanolide A ‑8.74 PHE A: 628, LEU A: 579, LEU: 551, LYS A: 581, SER A: 698, SER A: 633, ILE A: 559
Withaferin A ‑9.51 ARG A: 715, PRO A: 700, ASN A: 673, LEU A: 680, ILE A: 559, LEU A: 551, SER A: 633, LYS A: 677, THR A: 
555
Withanone ‑9.15 LEU A: 551, LYS A: 581, PHE A: 620, LEU A: 579, ILE A: 559, LYS A: 677, ASN A: 678, GLY A: 554, THR A: 
555
SYK Withanolide A ‑8.85 VAL A: 385, ALA A: 400, MET A: 450, LEU A: 501, LYS A: 458, PRO A: 455, GLN A: 462, TYR A: 459, LEU A: 
453
Withaferin A ‑9.19 GLU A: 452, MET A: 450, LEU A: 377, ALA A: 400, LYS A: 402, GLU A: 420, ASP A: 512, SER A: 511, PRO A: 
455, LEU A: 501
Withanone ‑8.11 LEU A: 377, ALA A: 451, ALA A: 400, GLU A: 452, MET A: 450, VAL A: 385, LEU A: 501, SER A: 511, MET 
A: 448, LYS A: 402, ASP A: 512
PDGFRB Withanolide A ‑7.38 LEU A: 28, TRP A: 32, LYS A: 35, ARG A: 37, LEU A: 31, TYR A: 38
Withaferin A ‑7.37 MET B: 30, ILE A: 27, SER A: 24, LEU A: 31, LEU A: 28, ILE A: 26, GLN B: 33
Withanone ‑7.41 ILE B: 26, ILE B: 29, LYS B: 34, LYS A: 35, LEU A: 31, PRO B: 36, MET B: 30
MAPK1 Withanolide A ‑8.68 GLU A: 33, VAL A: 39, LYS A: 114, ILE A: 31, ILE A: 84, LEU A: 156, ALA A: 52
Withaferin A ‑8.51 PRO A: 356, ASP A: 88, ILE A: 89, GLN A: 355, ILE A: 90, PRO A: 93, ARG A: 91, ALA A: 92
Withanone ‑9.43 PHE A: 354, ARG A: 353, LEU A: 76, ARG A: 79, HIS A: 80, ILE A: 83
MAPK8 Withanolide A ‑8.99 LYS A: 300, ILE A: 310, LEU A: 241, LEU A: 302, ILE A: 304, ASP A: 305, VAL A: 303
Withaferin A ‑8.72 SER A: 34, GLY A: 33, VAL A: 40, VAL A: 158, ALA A: 53, MET A: 111
Withanone ‑9.13 HIS A: 82, ALA A: 332, PRO A: 335, LYS A: 336, CYS A: 79, ASN A: 81, HIS A: 141, PRO A: 333
MAPK14 Withanolide A ‑9.51 TYR A: 35, VAL A: 38, ALA A: 51, PHE A: 169, LYS A: 53, LEU A: 55, SER A: 56, HIS A: 64, THR A: 68, ARG 
A: 67
Withaferin A ‑9.02 LEU A: 75, LEU A: 74, ARG A: 149, HIS A: 148, ARG A: 189
Withanone ‑9.46 LEU A: 55, GLU A: 71, HIS A: 64, ARG A: 67, LEU A: 104, LYS A: 53, ALA A: 51, VAL A: 38, PHE A: 169, 
SER A: 56
PRKCD Withanolide A ‑8.12 PHE A: 243, THR A: 242, SER A: 240, ASN A: 267, LYS A: 260, TYR A: 236
Withaferin A ‑7.37 TYR A: 236, MET A: 239, TYR A: 238, SER A: 240, PRO A: 241, PHE A: 243, ASP A: 245, CYS A: 244, GLY A: 
248, THR A: 242, LYS A: 260, ASN A: 267 
Withanone ‑7.71 PHE A: 243, THR A: 242, SER A: 240, MET A: 239, LYS A: 260, TYR A: 236, ASN A: 267
The residues forming hydrogen bonds with the withanolides are highlighted in grey
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generation in glutathione depleted cells (Susnow et al., 2009). 
The ROS mediated activation of MAPK pathway also suppresses 
the BCL2 expression in the cells (Changchien et al., 2015). The 
decreased levels of BCL2 were observed in COVID-19 mortality 
cases than in COVID-19 survivors (Lorente et al., 2021). On the 
other hand, withaferin A pretreatment has shown the reversal of 
BCL2 downregulation in bromobenzene induced mice models 
accompanied by decrease in the levels of inflammatory cytokines 
TNFα and IL1β along with the restoration of antioxidant 
enzymes levels that were suppressed by bromobenzene (Vedi 
& Sabina, 2016). These studies implicate the upregulation of 
BCL2 protein by withaferin A to be used against COVID-19 
severity. Withanone has also shown to reduce NMDA (N-methyl 
D-aspartate) induced ROS production and maintained Bax/
BCL2 ratio significantly in neuron like cells (Dolado & Nebreda, 
2008). All the three withanolides expressed higher binding score 
towards BCL2 compared to all the other target genes.
Once inside the cells, viral components directly activate a 
series of signalling pathways leading to the post translational 
modification of P53 along with its negative regulator 
MDM2. The loss of MDM2 function leads to P53 mediated 
induction of viral growth by decreasing cell apoptosis as in 
viral infections like SARS-CoV, MERS-CoV, and SARSCoV-2 
PLP (Zauli et al., 2020). Thus MDM2 can also be regarded 
as a potential target anti antiviral drugs. The docking poses 
of the three bioactives with MDM2 shows the occupation 
of the same binding pocket but with a slight difference in 
orientation of the withanolides within the binding region. 
Like most of the growth factor receptors, Platelet derived 
growth factor receptor (PDGFRB) are known to play an 
important role in the progression of viral infections right from 
adhering the cell surface to altering the signalling pathways 
to aid in replication (Vrijens et al., 2019). Thus compounds 
targeting the PDGFRB can be used as potent anti viral drugs. 
All the three withanolides were found to interact with the 
PDGFRB protein with withanolide A showing maximum 
interaction. The anti-inflammatory potential of FOXO 
transcription factors along with its role in maintaining normal 
cell physiology, regulating oxidative stress and immunity has 
turned the focus of researches for its role in viral infections. 
FOXO activation is reported to decrease the cytokine storm 
which is the main cause of mortality in COVID-19 patients 
and also produce immunological memory (Cheema et al., 
2021). The studies on the genes involved in COVID-19 
infection and its role in the underlying comorbidities 
revealed JAK2 as the core hub gene in cardiovascular 
disease, hypertension as well as kidney disorders (Barh 
et al., 2021). Therefore drugs targeting JAK2 can be used in 
COVID-19 patients with any of these underlying diseases. 
JAK2, along with SYK, JUN and PRKCD were present as 
the top 10 hub genes common in COVID-19 infection and 
Kidney disorders (Barh et al., 2021). Protein kinase C-delta 
(PKC-δ or PRKCD) are known to be phosphorylated at TYR 
512 and TYR 523 in response to H2O2 induced oxidative 
stress. This activation of the protein PRKCD leads to its 
translocation from the cytoplasm to the mitochondria which 
is required to bring about the apoptotic response of the cells 
under oxidative stress (Majumder et al., 2001). MAPK1 and 
MAPK8 were among the seven core gene set that were shared 
among diabetic pathways and COVID infection. Thus can 
act as suitable target for COVID-19 patients with diabetes. 
All the withanolides studied showed good scores against 
FOXO, JAK2 and JUN. Further MAPK14 was recognised as 
a protein for COVID patients with underlying, heart and 
kidney disorders (Barh et al., 2021). The pathway enrichment 
showed the association of MAPK with all the four selected 
pathways. Further all the three bioactives showed good 
docking conformations at different binding sites of MAPK1, 
MAPK8 and MAPK14.
CONCLUSION
Withania somnifera owing to its pharmacological activity has 
been evaluated against various diseases in various models in 
vitro and in vivo. But the role of individual metabolites of this 
plant on different pathways underlying the diseases has not 
been much explored. The present study is a computational 
approach to identify the possible pathway modulation by the 
withanolides to overcome oxidative stress. The above results 
show that all the three withanolides pocess nearly same binding 
energies with little similarity in the binding pockets and 
interacting residues. Thus these withanolides can be considered 
as a potential therapeutic compound for chronic diseases as it 
modulate several signalling pathways. But the combination of 
multiple components as in plant extracts or formulations may 
show synergistic activities to overcome stress in a better way than 
the individual lead hit. Further in vitro and in vivo examinations 
have to be conducted to study the potential activity of the 
individual withanolides as well as its combined activity when 
administered as plant extracts and formulations to overcome 
these pandemic diseases.
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